国际病毒学杂志
國際病毒學雜誌
국제병독학잡지
INTERNATIONAL JOURNAL OF VIROLOGY
2015年
1期
58-62
,共5页
阿昔洛韦%伐昔洛韦%利巴韦林%药效经济学
阿昔洛韋%伐昔洛韋%利巴韋林%藥效經濟學
아석락위%벌석락위%리파위림%약효경제학
Acyclovir%valaciclovir%Leigh Bhave Lin%pharmacodynamics of Economics
目的 探究带状疱疹患者使用阿昔洛韦、伐昔洛韦和利巴韦林等三种不同抗病毒药物实际应用中成本-疗效分析,为临床用药提供指导意义.方法 选取自2009年3月到2014年5月来我院就治并确诊为带状疱疹患者126例,采用随机抽样分为三组,其中A组采用阿昔洛韦抗疱疹病毒药物治疗,B组采用伐昔洛韦抗疱疹病毒药物治疗,C组采用利巴韦林广谱抗病毒药物治疗,观察分析三组患者临床有效率和治疗成本状况并计算成本/效果比.结果 治疗结束后,三组(A、B、C)患者治疗成本费分别为594.23±96.75元、721.77±101.32元、518.46±89.16元,相互之间存在显著统计学差异(t =6.003,3.729,9.509,P＜0.01).治疗效果方面,A组有效率(84.78％)和B组有效率(92.68％)远远超过C组有效率(71.79％),但A、B两组间不存在差异(x2=1.330,P＞0.05).住院时间上,A组患者要高于B组(t=2.254,P＜0.05),成本-效果比方面,A组(696.06)小于B组(772.11).结论 衡量治疗成本和疗效,从长远看,阿昔洛韦可以作为治疗首选药物,近期快速控制方面,伐昔洛韦可以作为首选药物.
目的 探究帶狀皰疹患者使用阿昔洛韋、伐昔洛韋和利巴韋林等三種不同抗病毒藥物實際應用中成本-療效分析,為臨床用藥提供指導意義.方法 選取自2009年3月到2014年5月來我院就治併確診為帶狀皰疹患者126例,採用隨機抽樣分為三組,其中A組採用阿昔洛韋抗皰疹病毒藥物治療,B組採用伐昔洛韋抗皰疹病毒藥物治療,C組採用利巴韋林廣譜抗病毒藥物治療,觀察分析三組患者臨床有效率和治療成本狀況併計算成本/效果比.結果 治療結束後,三組(A、B、C)患者治療成本費分彆為594.23±96.75元、721.77±101.32元、518.46±89.16元,相互之間存在顯著統計學差異(t =6.003,3.729,9.509,P＜0.01).治療效果方麵,A組有效率(84.78％)和B組有效率(92.68％)遠遠超過C組有效率(71.79％),但A、B兩組間不存在差異(x2=1.330,P＞0.05).住院時間上,A組患者要高于B組(t=2.254,P＜0.05),成本-效果比方麵,A組(696.06)小于B組(772.11).結論 衡量治療成本和療效,從長遠看,阿昔洛韋可以作為治療首選藥物,近期快速控製方麵,伐昔洛韋可以作為首選藥物.
목적 탐구대상포진환자사용아석락위、벌석락위화리파위림등삼충불동항병독약물실제응용중성본-료효분석,위림상용약제공지도의의.방법 선취자2009년3월도2014년5월래아원취치병학진위대상포진환자126례,채용수궤추양분위삼조,기중A조채용아석락위항포진병독약물치료,B조채용벌석락위항포진병독약물치료,C조채용리파위림엄보항병독약물치료,관찰분석삼조환자림상유효솔화치료성본상황병계산성본/효과비.결과 치료결속후,삼조(A、B、C)환자치료성본비분별위594.23±96.75원、721.77±101.32원、518.46±89.16원,상호지간존재현저통계학차이(t =6.003,3.729,9.509,P＜0.01).치료효과방면,A조유효솔(84.78％)화B조유효솔(92.68％)원원초과C조유효솔(71.79％),단A、B량조간불존재차이(x2=1.330,P＞0.05).주원시간상,A조환자요고우B조(t=2.254,P＜0.05),성본-효과비방면,A조(696.06)소우B조(772.11).결론 형량치료성본화료효,종장원간,아석락위가이작위치료수선약물,근기쾌속공제방면,벌석락위가이작위수선약물.
Objective To analysis the cost and antiviral drug efficacy of herpes zoster patients using acyclovir,valaciclovir and Leigh Bhave Lin,and to provide guidance for clinical treatment.Methods 126 patients diagnosed as herpes zoster were selected by random sampling and were divided into three groups from March 2009 to May 2014 in the hospital,group A using acyclovir resistant herpes simplex virus drug therapy,group B with valacyclovir against herpes simplex virus drug therapy,and group C with Leigh Bhave Lin broad-spectrum antiviral drug treatment.Clinical efficiency and cost of treatment status of the three groups patients were analyzed and the cost/effect ratio was calculate.Results After the treatment,three groups (A,B,C) of patients with treatment costs were respectively 594.23 + 96.75 yuan,721.77 ± 101.32 yuan,518.46 ± 89.16 yuan.There was significant difference between each other (t =6.003,3.729,9.509,P =0.000 ＜0.01).For the effect of treatment,the effective rate of A group (84.78％) and efficiency of group B (92.68％) were respectively far more than the C group's efficiency (71.79％),the two groups (A and B) has no difference (x2 =1.330,P =0.249 ＞0.05).For the time of hospitalization,the patients of A group than that of B group (t =2.254,P =0.027 ＜0.05).For the cost effectiveness ratio,A group (696.06) was lower than in group B (772.11).Conclusions For the measure of treatment efficacy and cost in the long run,acyclovir can be used as therapeutic drug of choice.For the recent rapid control,valacyclovir can be used as the preferred drug.
